Great news for NHS Lung Cancer patients

CCC’s long standing supporter AMGEN,  brings breakthrough drug to NHS for Lung Cancer patients

NHS lung cancer patients will be the first in Europe to be offered a revolutionary new drug which stops tumours growing by targeting the so-called “death star” mutation.

The cutting-edge therapy Sotorasib will be fast-tracked to NHS patients after being proven in clinical trials to stop lung cancer growing for seven months.

The drug’s adoption by NHS follows a 40 year search for a treatment for the mutation on the KRAS gene, present in a quarter of all tumours, which has been dubbed the “Death Star” because of its spherical appearance and impenetrable nature.

Around 600 NHS lung cancer patients a year will be given the drug initially in England, starting in the next few weeks thanks to an early-access deal.

Sotorasib, taken as a tablet, binds with the KRAS G12C mutation and makes it inactive, stopping cell division and cancer growth.

It is the first treatment of its kind and could represent a major breakthrough in treatments for some of the world’s other deadliest cancers including pancreatic and colorectal cancers.

NHS England, NICE and manufacturer Amgen have reached an agreement to enable early access to sotorasib for eligible lung cancer patients in England on a budget-neutral basis to the NHS while NICE completes its ongoing appraisal.

Dr Tony Patrikios, Executive Medical Director, Amgen UK and Ireland, said: “Amgen’s first-in-class medicine, sotorasib, is the culmination of a 40-year quest to target this cancer gene mutation which is known to drive the growth of certain cancers. As an oral targeted therapy, this represents a new option for specific non-small cell lung cancer patients, and we are delighted to partner with NHS England to make this treatment available to those patients who may benefit from it, as quickly as possible.”

Dr Nidhin Raj

 

Dr.Nidhin is a consultant radiation oncologist at Kerala,the southern part of India. He trained  at 2 of the oldest medical colleges of the country-govt medical college, Trivandrum and Madras medical college Chennai , he went on to have NHS training at the Royal Marsden Hospital,UK. He was Recipient of the prestigious Neil Joseph Fellowship and resident fellowship from YROC and presenter at various international conferences across the globe. He has held various high profile positions throughout the continent. He retains his Global leadership panel membership for fight cancer Global USA , Visiting faculty member at university of Kerala & was the past General secretary of Young radiation oncologists forum.
He has been a key associate and champion of CCC since 2016 in the capacity of a consultant,  for establishing accreditation and quality improvement of cancer centres across India and China. CCC are delighted to continue our collaboration and friendship with Dr Nidhin.

 

Expert Panel: Quality of Medicine

 

Earlier today (01/07/21) CCC facilitated a  Global Expert Virtual Panel and asked two questions: 1. Based on your experience, where can the most significant breakdown be, in the delivery of cancer patients who need them? and 2.Who are the key audiences that should be aware of these potential issues; How do you think we can reach them and what would compel them to take action?

Following a 2hr+ discussion, with each panelist providing great insight and innovative forward planning, CCC will capture the collective reflections and take them forward in a meaningful way. Watch this space for the next, exciting, ground breaking steps !

 

CCC to facilitate a Quality of Medicine Expert Panel on 1st July 2021

 

Quality of Medicine Expert Panel 1 July 2021

 

Cancer Care Commission will bring together a Global Expert panel to debate the issues and potential solutions in the delivery of high quality cancer medicines. The outcomes from the meeting will inform and shape a Crowdsourcing Campaign later in the year……watch this space for updates.

 

Quality of Medicine Initiative Objective:  Identify real-world insights and solutions for healthcare professionals in delivery of high-quality cancer medicines via an online Crowdsourcing Campaign*

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Hyuna Sung, PhD1; Jacques Ferlay, MSc, ME2; Rebecca L. Siegel, MPH1; Mathieu Laversanne, MSc2; Isabelle Soerjomataram, MD, MSc, PhD2; Ahmedin Jemal, DMV, PhD1; Freddie Bray, BSc, MSc, PhD2

CA CANCER J CLIN 2021;0:1–41
1
VOLUME 0 | NUMBER 0 | MONTH 2021
Abstract: This article provides an update on the global cancer burden using the
GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the
International Agency for Research on Cancer. Worldwide, an estimated 19.3 million
new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0
million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred
in 2020.

https://acsjournals.onlinelibrary.wiley.com/share/C7BIMUUUIYFIGFY4XJAB?target=10.3322/caac.21660

CCC retains ISQua membership

Cancer Care Commission

Is delighted to be once again accepted as an Institutional member of the International Society for Quality in Health Care (ISQua) ISQua is a global network of like-minded professionals dedicated to improving quality and safety in health care around the world, and are recognised as part of an international community, working to enhance patient safety and quality.

 

Meet the Team …in China

The team will be led by our long term partner, Dr Fred Sun, who has a long and successful relationship with CCC. Fred has  wide and robust international experience working in Healthcare and will provide leadership and direction for the team.

 

 

 

 

 

 

 

 

 

 

 

Dr Sun will be joined by Ms Andrea Gu, VP For Operations and Quality Assurance.

 

CCC establishes Full time China based Team

Exciting news as CCC establish a WFOE (Wholly Foreign Owned Enterprise) in Beijing, China. Executive Director Calum Kerr said ” This is a great step forward, to establish our full time China based team, who will be able to drive forward with our strategic plans for supporting Cancer Care in China. We are fortunate to have an experienced, dedicated team of well respected professionals, who understand the needs and demands of China, in relation to Cancer Care.” The WFOE will be known as ‘Beijing Kangzekaier Medical Management Consulting Co., LTD.’

Management of Oncology Patients during #COVID19 Pandemic; Webinar 18th April.